AAAP Advanced Accelerator Applications S.A.

57.70
+0.07  (0%)
Previous Close 57.63
Open 56.90
Price To book 7.46
Market Cap 2548411551
Shares 44,166,578
Volume 242,739
Short Ratio 1.33
Av. Daily Volume 109,876

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated September 2016
Apoptosis
Necrosis
Phase 2 initiated September 2016
Annexin V-128
Early Breast Cancer
Positive opinion by EMA released in October 2016.
Somakit-TOC
Neuroendocrine cancers
CRL issued December 21, 2016. NDA to be resubmission announced July 27, 2017 with new PDUFA date January 26, 2018.
Lutathera
Inoperable progressive midgut NETs
Approved June 1, 2016.
Somakit-TATE
Neuroendocrine tumor diagnosis
Ongoing
Annexin V-128
Rheumatoid arthritis and ankylosing spondylitis

Latest News

  1. CORRECTING and REPLACING -- Advanced Accelerator Applications S.A.
  2. Advanced Accelerator Applications (AAAP) in Focus: Stock Moves 7.5% Higher
  3. Advanced Accelerator Applications SA :AAAP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 6, 2017
  4. Advanced Accelerator Applications and FUJIFILM RI Pharma, Co., LTD Announce First Patient in Bridging Study in Japan for Lutetium Lu 177 Dotatate* (Lutathera®)
  5. Advanced Accelerator Applications Reports 32% Sales Growth for Second Quarter 2017
  6. Advanced Accelerator Gets Action Date for Lutathera from FDA
  7. Advanced Accelerator Applications Announces New Prescription Drug User Fee Act (PDUFA) date of January 26, 2018, for Lutetium Lu 177 Dotatate (Lutathera®)
  8. Zacks.com featured highlights: Columbus McKinnon, The New York Times, Advanced Accelerator Applications, Enanta Pharmaceuticals and Caesars Entertainment
  9. Advanced Accelerator Applications Completes Resubmission of NDA for Lutetium Lu 177 Dotatate (Lutathera®) to FDA
  10. Galmed Pharmaceuticals (GLMD) Catches Eye: Stock Gains 15.7%
  11. Advanced Accelerator Applications Announces Positive CHMP Opinion Recommending Approval of Lutetium 177Lu Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors
  12. ETFs with exposure to Advanced Accelerator Applications SA : July 11, 2017
  13. ETFs with exposure to Advanced Accelerator Applications SA : June 27, 2017
  14. Advanced Accelerator Applications SA :AAAP-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017
  15. Blog Coverage Chembio Announces Major Leadership Shuffle as CEO Sperzel Takes Medical Leaves